ID: ALA266800

Max Phase: Preclinical

Molecular Formula: C18H22N2O3

Molecular Weight: 314.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(CCCCCOc2ccc(C3=NCCO3)cc2)on1

Standard InChI:  InChI=1S/C18H22N2O3/c1-14-13-17(23-20-14)5-3-2-4-11-21-16-8-6-15(7-9-16)18-19-10-12-22-18/h6-9,13H,2-5,10-12H2,1H3

Standard InChI Key:  IWZDYGHUSXWPPM-UHFFFAOYSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 314.39

Molecular Weight (Monoisotopic): 314.1630

AlogP: 3.55

#Rotatable Bonds: 8

Polar Surface Area: 56.85

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 3.99

CX LogP: 3.26

CX LogD: 3.26

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.70

Np Likeness Score: -0.84

References

1. Diana GD, Kowalczyk P, Treasurywala AM, Oglesby RC, Pevear DC, Dutko FJ..  (1992)  CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.,  35  (6): [PMID:1313108] [10.1021/jm00084a005]

2. Diana GD, Treasurywala AM, Bailey TR, Oglesby RC, Pevear DC, Dutko FJ..  (1990)  A model for compounds active against human rhinovirus-14 based on X-ray crystallography data.,  33  (5): [PMID:2158559] [10.1021/jm00167a006]

3. Leclerc F, Cedergren R..  (1998)  Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex.,  41  (2): [PMID:9457241] [10.1021/jm970372r]

4. Diana GD, McKinlay MA, Otto MJ, Akullian V, Oglesby C..  (1985)  [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating.,  28  (12): [PMID:2999407] [10.1021/jm00150a025]

5. Diana GD, Oglesby RC, Akullian V, Carabateas PM, Cutcliffe D, Mallamo JP, Otto MJ, McKinlay MA, Maliski EG, Michalec SJ..  (1987)  Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.,  30  (2): [PMID:3027340] [10.1021/jm00385a021]

6. Bailey TR, Diana GD, Mallamo JP, Vescio N, Draper TL, Carabateas PM, Long MA, Giranda VL, Dutko FJ, Pevear DC..  (1994)  An evaluation of the antirhinoviral activity of acetylfuran replacements for 3-methylisoxazoles. Are 2-acetylfurans bioisosteres for 3-methylisoxazoles?,  37  (24): [PMID:7990117] [10.1021/jm00050a014]

7. Diana GD, Cutcliffe D, Oglesby RC, Otto MJ, Mallamo JP, Akullian V, McKinlay MA..  (1989)  Synthesis and structure-activity studies of some disubstituted phenylisoxazoles against human picornavirus.,  32  (2): [PMID:2913305] [10.1021/jm00122a027]

8. Klebe G, Abraham U..  (1993)  On the prediction of binding properties of drug molecules by comparative molecular field analysis.,  36  (1): [PMID:8380615] [10.1021/jm00053a009]

9. Egorova A, Ekins S, Schmidtke M, Makarov V..  (2019)  Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.,  178  [PMID:31226653] [10.1016/j.ejmech.2019.06.008]

Source

Source(1):

• Scientific Literature